Herb-antitumour drug interaction risks: retrospective integrative oncology study.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES BMJ Supportive & Palliative Care Pub Date : 2025-02-26 DOI:10.1136/spcare-2024-005098

Noah Samuels, Shir Shapira, Eran Ben-Arye

{"title":"Herb-antitumour drug interaction risks: retrospective integrative oncology study.","authors":"Noah Samuels, Shir Shapira, Eran Ben-Arye","doi":"10.1136/spcare-2024-005098","DOIUrl":null,"url":null,"abstract":"Objectives: The use of herbal medicine is widespread among oncology patients, with potentially negative interactions with anticancer drugs. This study identified herbal products being used among a cohort of oncology patients, assessing the risk for an herb-drug interaction.Methods: Herbal medicine use was examined among 42 oncology patients, identifying potential herb-drug interactions using four online sites. The risk for an interaction was scored using the Working Group on Pharmacotherapy and Drug Information of the Royal Dutch Association for the Advancement of Pharmacy (KNMP).Results: Most patients (62%) reported herbal medicine use, with 70 products identified; 8 herbs and 13 herbal formulas with unidentified components; and 24 anticancer drugs. Herbal medicine use was more prevalent among female patients (p=0.038), with only nine potential herb-drug interactions identified on at least one site. A maximal KNMP Score of 1 (ie, incomplete published case report) was found with only one interaction.Conclusions: The risk for interactions between herbal products and anticancer drugs is difficult to predict, with online search engines providing limited and inconsistent information. Clinical implications of herb-antitumor drug interactions need to be better understood, enabling patients and their oncology healthcare providers to make informed decisions regarding their care.","PeriodicalId":9136,"journal":{"name":"BMJ Supportive & Palliative Care","volume":" ","pages":"245-248"},"PeriodicalIF":1.8000,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ Supportive & Palliative Care","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/spcare-2024-005098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The use of herbal medicine is widespread among oncology patients, with potentially negative interactions with anticancer drugs. This study identified herbal products being used among a cohort of oncology patients, assessing the risk for an herb-drug interaction.

Methods: Herbal medicine use was examined among 42 oncology patients, identifying potential herb-drug interactions using four online sites. The risk for an interaction was scored using the Working Group on Pharmacotherapy and Drug Information of the Royal Dutch Association for the Advancement of Pharmacy (KNMP).

Results: Most patients (62%) reported herbal medicine use, with 70 products identified; 8 herbs and 13 herbal formulas with unidentified components; and 24 anticancer drugs. Herbal medicine use was more prevalent among female patients (p=0.038), with only nine potential herb-drug interactions identified on at least one site. A maximal KNMP Score of 1 (ie, incomplete published case report) was found with only one interaction.

Conclusions: The risk for interactions between herbal products and anticancer drugs is difficult to predict, with online search engines providing limited and inconsistent information. Clinical implications of herb-antitumor drug interactions need to be better understood, enabling patients and their oncology healthcare providers to make informed decisions regarding their care.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

草药与抗肿瘤药物相互作用的风险：回顾性综合肿瘤学研究。

目的：肿瘤患者广泛使用中草药，这可能会与抗癌药物产生不良相互作用。本研究确定了一批肿瘤患者使用的草药产品，并评估了草药与药物相互作用的风险。方法：研究了 42 名肿瘤患者使用草药的情况，通过四个在线网站确定了潜在的草药与药物相互作用。采用荷兰皇家药学促进协会（KNMP）的药物疗法和药物信息工作组对相互作用的风险进行评分：大多数患者（62%）报告使用了草药，其中有 70 种产品被确认；8 种草药和 13 种成分不明的草药配方；以及 24 种抗癌药物。草药在女性患者中使用更为普遍（p=0.038），仅在至少一个部位发现了 9 种潜在的草药-药物相互作用。仅发现一种相互作用的最高 KNMP 得分为 1（即未完成发表的病例报告）：结论：草药产品与抗癌药物之间发生相互作用的风险很难预测，在线搜索引擎提供的信息有限且不一致。需要更好地了解中草药与抗肿瘤药物相互作用的临床影响，使患者及其肿瘤医护人员能够在知情的情况下做出治疗决定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMJ Supportive & Palliative Care Medicine-Medicine (miscellaneous)

CiteScore

4.60

自引率

7.40%

发文量

170

期刊介绍： Published quarterly in print and continuously online, BMJ Supportive & Palliative Care aims to connect many disciplines and specialties throughout the world by providing high quality, clinically relevant research, reviews, comment, information and news of international importance. We hold an inclusive view of supportive and palliative care research and we are able to call on expertise to critique the whole range of methodologies within the subject, including those working in transitional research, clinical trials, epidemiology, behavioural sciences, ethics and health service research. Articles with relevance to clinical practice and clinical service development will be considered for publication. In an international context, many different categories of clinician and healthcare workers do clinical work associated with palliative medicine, specialist or generalist palliative care, supportive care, psychosocial-oncology and end of life care. We wish to engage many specialties, not only those traditionally associated with supportive and palliative care. We hope to extend the readership to doctors, nurses, other healthcare workers and researchers in medical and surgical specialties, including but not limited to cardiology, gastroenterology, geriatrics, neurology, oncology, paediatrics, primary care, psychiatry, psychology, renal medicine, respiratory medicine.